A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

faridoxorubicin (AVA6000) - Avacta

https://www.abstractsonline.com/pp8/#!/20272/presentation/11478

U. Banerji 1; N. Cook 2; A. Anthoney 3; R. Plummer 4; W. D. Tap 5; J. T. R. Evans 6; L. D. Cranmer 7; C. Plummer 8; P. Loadman 9; G. Lahu 10; H. S. Jones 9; N. Kinnersley 11; F. McLaughlin 12; C. Twelves8

Mar 6, 2024